StockData
Actinium Pharmaceuticals, Inc. logo

Actinium Pharmaceuticals, Inc. (ATNM) stock

ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)

Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –

Actinium Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Actinium Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.12M, down 33.3% year over year. For fiscal 2025 it was $21.12M, down 29.7% from the year before. Over ten years it grew 4.6% a year on average. The highest annual figure on record is $38.67M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$21.12M-29.7%
FY2024Dec 31, 2024$30.05M-22.3%
FY2023Dec 31, 2023$38.67M+67.1%
FY2022Dec 31, 2022$23.14M+28.3%
FY2021Dec 31, 2021$18.03M+12.1%
FY2020Dec 31, 2020$16.09M-2.8%
FY2019Dec 31, 2019$16.55M-3.2%
FY2018Dec 31, 2018$17.09M-3.5%
FY2017Dec 31, 2017$17.72M-0.6%
FY2016Dec 31, 2016$17.83M+32.0%
FY2015Dec 31, 2015$13.50M+10.1%
FY2014Dec 31, 2014$12.27M+294.5%
FY2013Dec 31, 2013$3.11M-9.6%
FY2012Dec 31, 2012$3.44M+962.6%
FY2011Dec 31, 2011$323.79K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.38M+10.2%
Q1 FY2026Mar 31, 2026$4.20M-45.4%
Q4 FY2025Dec 31, 2025$4.30M-10.7%
Q3 FY2025Sep 30, 2025$4.25M-56.5%
Q2 FY2025Jun 30, 2025$4.88M-44.7%
Q1 FY2025Mar 31, 2025$7.70M+16.1%
Q4 FY2024Dec 31, 2024$4.81M-40.7%
Q3 FY2024Sep 30, 2024$9.77M-15.9%
Q2 FY2024Jun 30, 2024$8.83M-20.4%
Q1 FY2024Mar 31, 2024$6.64M-15.5%
Q4 FY2023Dec 31, 2023$8.12M+10.7%
Q3 FY2023Sep 30, 2023$11.62M+71.6%
Q2 FY2023Jun 30, 2023$11.08M+137.7%
Q1 FY2023Mar 31, 2023$7.85M+79.7%
Q4 FY2022Dec 31, 2022$7.33M+35.4%
Q3 FY2022Sep 30, 2022$6.77M+43.8%
Q2 FY2022Jun 30, 2022$4.66M+28.4%
Q1 FY2022Mar 31, 2022$4.37M+2.2%
Q4 FY2021Dec 31, 2021$5.42M+16.7%
Q3 FY2021Sep 30, 2021$4.71M+24.3%
Q2 FY2021Jun 30, 2021$3.63M+3.5%
Q1 FY2021Mar 31, 2021$4.28M+3.0%
Q4 FY2020Dec 31, 2020$4.64M+37.5%
Q3 FY2020Sep 30, 2020$3.79M-21.6%
Q2 FY2020Jun 30, 2020$3.51M-12.5%
Q1 FY2020Mar 31, 2020$4.15M-4.3%
Q4 FY2019Dec 31, 2019$3.37M-33.5%
Q3 FY2019Sep 30, 2019$4.83M+14.3%
Q2 FY2019Jun 30, 2019$4.01M+20.4%
Q1 FY2019Mar 31, 2019$4.34M-2.9%
Q4 FY2018Dec 31, 2018$5.07M+38.1%
Q3 FY2018Sep 30, 2018$4.23M-15.9%
Q2 FY2018Jun 30, 2018$3.33M-25.1%
Q1 FY2018Mar 31, 2018$4.47M-2.3%
Q4 FY2017Dec 31, 2017$3.67M-13.2%
Q3 FY2017Sep 30, 2017$5.03M-11.6%
Q2 FY2017Jun 30, 2017$4.45M–
Q1 FY2017Mar 31, 2017$4.57M–
Q4 FY2016Dec 31, 2016$4.23M–
Q3 FY2016Sep 30, 2016$5.69M–

More Actinium Pharmaceuticals figures

See a number that looks wrong?